Selling medical devices requires navigating a layered system of regulatory clearances, hospital procurement committees, and purchasing contracts before your product reaches a single patient. Unlike most B2B sales, the person who uses the device (the physician), the person who pays for it (the hospital or insurer), and the person who approves its purchase (a committee or network) are usually three different entities. Understanding each layer is what separates reps who close deals from those who stall out.
Know Your Device’s Regulatory Classification
The FDA classifies every medical device into one of three classes based on the risk it poses to patients. Class I covers the lowest-risk products (think bandages, tongue depressors), Class II includes moderate-risk devices (powered wheelchairs, pregnancy tests), and Class III covers the highest-risk devices (pacemakers, heart valves). The class your device falls into determines your path to market and shapes how you sell it.
About 74% of Class I devices are exempt from premarket notification entirely. Most Class I and Class II devices that aren’t exempt require a 510(k) submission, which demonstrates your device is substantially equivalent to something already on the market. Class III devices typically need a premarket approval application (PMA), a much more rigorous and expensive process involving clinical trials. When you’re selling, the regulatory pathway your device cleared signals credibility. A PMA-cleared device carries more clinical evidence behind it, which becomes a selling point when you’re sitting in front of a hospital committee.
Understand Who Actually Makes Buying Decisions
Hospitals rarely let individual physicians unilaterally choose which devices to purchase. Most buying decisions flow through a Value Analysis Committee (VAC), a cross-functional group that includes clinicians, supply chain specialists, and finance staff. Their primary metric is value, defined as quality divided by cost. They will ask whether your device improves outcomes compared to what they already use, and whether those improvements justify any price difference. If a proposed product addresses the same clinical need as an existing one, the committee’s default position is skepticism: does this add cost without improving quality?
Supply chain and finance members of the committee will run pricing comparisons and check reimbursement rates before the group even discusses clinical merits. Many orthopedic and surgical products, for instance, have limited patient outcome data beyond safety reports and recall information. If your device has strong clinical data showing meaningful outcome differences, that’s a genuine competitive advantage, because most devices in your category probably don’t.
The Role of GPOs and IDNs
Two entities sit above individual hospitals and heavily influence what gets purchased. Group Purchasing Organizations (GPOs) negotiate bulk pricing on behalf of thousands of hospitals and clinics. Even when a facility doesn’t mandate using the GPO contract, the negotiated pricing tiers make GPO-listed products far more financially attractive. If your device isn’t on the GPO contract, you’re fighting an uphill cost battle at every facility that belongs to that organization.
Integrated Delivery Networks (IDNs) are healthcare systems made up of multiple hospitals, clinics, and care facilities that centralize their purchasing decisions. An IDN controls vendor selection, pricing approvals, and product standardization across all its sites. Winning a single IDN contract can open dozens of facilities at once, but losing it locks you out of that entire system. Knowing which GPOs and IDNs a target facility belongs to, and what contract tiers apply, is essential preparation before any sales call.
Build Your Clinical and Economic Evidence
FDA clearance gets your device on the market, but it often isn’t enough to get it purchased or reimbursed. Commercial insurers frequently require clinical validity and utility evidence beyond what the FDA demanded. Medicare evaluates evidence in three stages: the quality of individual studies, the relevance of those findings to the Medicare population (predominantly over 65 with at least one chronic condition), and the overall direction and magnitude of risks versus benefits.
The hierarchy of evidence that payers respect, from strongest to weakest: randomized controlled trials, non-randomized controlled trials, prospective cohort studies, retrospective case-control studies, cross-sectional studies, registry surveillance data, consecutive case series, and single case reports. If your clinical story rests on case reports alone, expect resistance from both payers and hospital committees. If you have randomized trial data showing meaningfully better outcomes, measure those in economic terms too. Payers want to see that better outcomes translate into cost savings or efficiency gains, not just statistical significance on a clinical endpoint.
Medicare sometimes uses a pathway called Coverage with Evidence Development, where they’ll cover a new device on the condition that it’s used in approved clinical studies or that outcome data is collected in a registry. If your device falls into this category, understanding the data collection requirements becomes part of your sales pitch: you need to help hospitals see participation as manageable, not burdensome.
Sell on Total Cost, Not Just Price
Value-based procurement is reshaping how hospitals evaluate device purchases. The price on your invoice is only one number in a much larger equation. Total cost of ownership includes staff training, installation and relocation costs, software upgrades, maintenance contracts, overhead, and depreciation. A device with a lower sticker price but expensive consumables or frequent service needs can cost more over its lifetime than a higher-priced competitor with lower ongoing expenses.
When presenting to a VAC or procurement team, frame your device in terms of all costs and all outcomes. If your product reduces operating room time by 15 minutes per procedure, quantify what that means across hundreds of cases per year. If it lowers readmission rates, calculate the financial impact under bundled payment models where the hospital absorbs readmission costs. The shift toward value-based purchasing means linking your pricing directly to quality and efficiency gains. Physician preference still matters, but those preferences take a back seat when the committee’s analysis shows a device adds cost without adding value.
Get Credentialed Before You Walk In
You cannot enter most clinical areas of a hospital without completing vendor credentialing, a process that varies by facility but follows a common pattern. Standard requirements include verification of employment and training, proof of vaccinations (MMR, Hepatitis B, Tetanus, Tdap, influenza, and often COVID-19), a tuberculosis test, drug screening, federal and state criminal background checks, proof of insurance coverage, HIPAA compliance training, and safety training covering bloodborne pathogens.
Each hospital or health system may add its own requirements on top of these. Many use third-party credentialing platforms, so maintaining current records in those systems saves time when onboarding with new facilities. If you sell devices used in the operating room, expect additional protocols around sterile environments, traffic patterns, and appropriate conduct during procedures. Letting your credentials lapse, even briefly, can lock you out of a facility at the worst possible time.
Track Payments Under the Sunshine Act
Every transfer of value you make to a physician or teaching hospital is reportable under the Open Payments program (commonly called the Sunshine Act). For the 2026 program year, any individual payment or transfer of value of $13.82 or more must be reported. If the total of all small payments to a single covered recipient exceeds $138.13 in a calendar year, every payment to that person must be reported, including the ones below the individual threshold. This covers meals, consulting fees, travel reimbursement, educational materials, and speaker honoraria.
All reported data becomes publicly searchable. Physicians are aware of this, and some are cautious about accepting anything that inflates their profile on the database. Being transparent about reporting from the start builds trust. More practically, your company’s compliance team will require meticulous tracking, so build that habit into every interaction rather than trying to reconstruct records later.
Selling Outside the United States
The European Union operates under the Medical Device Regulation (EU 2017/745), which replaced the older Medical Device Directives. The MDR places heavier emphasis on a lifecycle approach to safety, backed by clinical data at every stage. Manufacturers must maintain systems for risk management and quality management, conduct clinical evaluations, compile technical documentation, and complete a conformity assessment procedure. Every manufacturer needs a named person responsible for regulatory compliance. Companies based outside the EU must contract with an authorized representative inside the EU or EEA.
The device’s risk class determines what’s required for CE marking, which is the certification that allows you to sell in Europe. Class I devices with lower risk can often self-certify, but Class IIa, IIb, and Class III devices all require the involvement of a Notified Body, an independent organization authorized to assess conformity. Implantable Class III devices and some Class IIb devices also go through a clinical evaluation consultation with an independent expert panel. The process is time-consuming and expensive, so most companies secure their home market regulatory clearance first, then pursue EU certification as a second phase.
Practical Steps to Close Your First Sales
Start by mapping the decision-making structure at your target facilities. Identify the GPO contracts in place, the IDN affiliations, and the composition of the Value Analysis Committee. Your initial conversations with physicians build clinical interest, but the deal closes when you present a compelling case to the committee combining outcome data, total cost analysis, and reimbursement clarity.
Bring more than a product demo. Prepare a dossier that includes your strongest clinical evidence, a total cost of ownership comparison against incumbent devices, reimbursement coding information, and a clear implementation plan covering training and support. If your device is new to the market and outcome data is still limited, consider proposing an evaluation period or pilot program. Some hospitals will trial a device on a limited basis before committing to a system-wide contract, and a successful pilot generates the internal champion you need.
Relationships still matter in this industry, but they’re built on credibility and follow-through, not meals and golf outings. The rep who can walk a surgeon through a clinical paper, answer a CFO’s reimbursement question, and navigate a GPO contract review in the same week is the one who earns long-term business.